Daily evidence digest
7 September 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

SARS-CoV-2 vaccination in immune-mediated inflammatory diseases, anakinra for early treatment, anti-SARS-CoV-2 seroprevalence in the US

Peer reviewed journals featured:
- A systematic review on SARS-CoV-2 vaccination in immune-mediated inflammatory diseases [here](#)
- A randomised controlled trial of anakinra for early treatment of COVID-19 [here](#)
- Narrative reviews on:
  - Major registries of people with cancer diagnosed with COVID-19 [here](#)
  - Embedding behaviours that protect against COVID-19 transmission in the UK [here](#)
- Observational studies on:
  - Estimated US infection- and vaccine-induced SARS-CoV-2 seroprevalence [here](#)
  - Emergency Department encounters among youth with suicidal thoughts or behaviours in Northern California [here](#)
  - Antibody response to the Pfizer vaccine in patients undergoing haemodialysis [here](#)
  - Ascorbic acid as adjunctive therapy in critically ill COVID-19 patients [here](#)
- A modelling study on outcomes associated with social distancing policies in St Louis [here](#)
- Commentary on:
  - Emotional supportive care for first-degree relatives of deceased COVID-19 people [here](#)
  - A spike in stillbirths during COVID-19 in India [here](#)

Letters and correspondence discussed:
- The rate of recurrent Guillain-Barré syndrome after Pfizer vaccine [here](#)
- Association between exposure characteristics and the risk for COVID-19 infection among healthcare workers, with and without vaccination [here](#)
- SARS-CoV-2 antibody responses by age among recipients of the Pfizer and Moderna vaccine [here](#)

Pre-peer review articles featured:
- COVID-19 vaccine effectiveness during a Delta variant surge in Oregon [here](#)
- Viral loads of Delta variant breakthrough infections following Pfizer vaccination and booster [here](#)
- Monitoring populations at increased risk for SARS-CoV-2 infection in the UK [here](#)
- Mitigating the fourth wave of COVID-19 in Ontario, Canada [here](#)
- The risk of hospitalisation for cases of the Delta and Alpha variants in Norway [here](#)
Guidance and reports

- The Therapeutic Goods Administration (TGA) issued provisional approval of the Moderna vaccine for people aged 12-17 years here.
- The American Society of Haematology updated its guidelines on the use of anticoagulation for thromboprophylaxis in COVID-19 patients here.
- Public Health England published an update on SARS-CoV-2 variants of concern and variants under investigation here.

News and blogs

- The UK's Joint Committee on Vaccination and Immunisation does not recommend universal vaccination for children aged 12-15 years old here.
- An open letter to the unvaccinated here.
- India’s DNA (ZyCoV-D) COVID-19 vaccine is a world-first here.
- Calming the cytokine storm in COVID-19 here.

Click here to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on COVID-19 transmission, SARS-CoV-2 vaccines, and variants of concern, post-acute sequelae of COVID-19 (PASC), surgery and COVID-19, and rapid testing.

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.